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Background: The most important metabolic impairment in patients with advanced liver disease is
characterized by low levels of circulating branched chain amino acids (BCAAs). The etiology of such
abnormal amino acid metabolism is multifactorial including protein restricted diet or inadequate
nutritional intake as in protein energy malnutrition. Multiple studies report the beneﬁcial effects
of BCAAs supplementation to improve plasma amino acids imbalance, several neurologic diseases,
protein energy malnutrition, and subsequently the survival rate of cirrhotic patients.
Methods: In the present study we used a protein substitution technique to synthesize a new pro-
cessed cheese as a dairy source rich in BCAAs, with low phenylalanine content manufactured from
Ras cheese, kariesh cheese, butter oil and phenylalanine-free milk. Chemical composition, amino
acids analysis, rheological properties and sensory evaluation were done to all of the cheese samples.
L-Phenylalanine was selected to induce hepatic and brain affections in Begg Albino strain c (BALB/c)
mice model. Effect of 2.5%, 5% and 10% protein-replacement cheese formulas was evaluated among
mice groups including histopathological sections of the liver and brain; colorimetric determination1372092.
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122 H.A.M. El-Shazly et al.for liver enzymes; serum total and differential cholesterol proﬁle, serum albumin, globulin and total
protein along with phenylalanine levels determinations.
Results: Analysis of the processed cheese sample with 10%protein substitution revealed that the pro-
tein content was 7.42 mg/g (about 50% of the content in the standard processed cheese) while fat con-
tent, acidity and moisture were nearly the same. The sensory score for all the formulas ranged from
79–88. Highest content of BCAAs along with least phenylalanine content was attained in the pro-
cessed cheese with 10% protein substitution. Weight of mice fed on different substitution formulas
ranged from 22.8 ± 2.2–24.66 ± 2.5 g compared with 17.8 ± 1.9 g in the untreated diseased mice
(P< 0.05). Serumphenylalanine was 1.822 ± 0.42 mg/dl in themice fed on 10%protein substitution
formula compared to 6.2 ± 1.32 mg/dl in the untreated mice (P< 0.01). There was a highly signif-
icant difference (P< 0.01) between untreated mice and mice fed on 10% substitution cheese formula
as regards the serum protein, Aspartate Transaminase (AST) and Alanine Transaminase (ALT). The
improvement in histopathological ﬁndings wasmore apparent in themice fed on 10% formula cheese.
Conclusion: Themanufactured processed cheese with 10% protein substitution was proved to have a
more nutritional therapeutic potential that can help in the implementation of dietary management in
many medical and genetic disorders with liver and brain affections.
 2010 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The restriction of dietary protein has long been considered a
mainstay in the therapy of hepatic encephalopathy. More re-
cently, it has been recognized that protein – energy malnutri-
tion is frequent in advanced liver disease and may adversely
affect the patient’s outcome [1]. Cirrhosis represents the ﬁnal
stage of many chronic liver diseases and is associated with
more or less pronounced hyponutrition. The most important
metabolic impairment in patients with advanced liver disease
is the change in amino acid metabolism. The plasma levels of
branched chain amino acids (BCAA) are decreased [2]. Multi-
ple studies report the beneﬁcial effects of branched-chain ami-
no acids supplementation, including improved metabolic
proﬁles as measured by protein sparing and clinical improve-
ment of hepatic encephalopathy. Increasing evidences show
that the oxidative stress is involved in a large number of
diseases as arteriosclerosis, diabetes, phenylketonuria, neuro-
degenerative disorders, such as Alzheimer’s disease and
Parkinson’s disease; cancer and aging among others [3]. Many
of the features of BCAAs metabolism in tumor-bearing state
are similar to other disease states that feature involuntary
weight loss and skeletal muscle atrophy. These states are gen-
erally characterized by altered BCAAs availability (low
BCAAs intake, elevated rate of BCAAs oxidation, and gluco-
neogenesis), which are concurrent with the activation of prote-
olysis and the suppression of protein synthesis in skeletal
muscles. These features are the basis of suggestions for dietary
supplementation with BCAA or their metabolites [4]. In pa-
tients with phenylketonuria, a higher dosage of the protein
substitute appeared to contribute to lower blood phenylalanine
concentrations [5] with the branched-chain amino acids
(BCAAs) inﬂuencing brain function by modifying large neutral
amino acid (LNAA) transport at the blood–brain barrier. The
chronic uses of BCAA supplementations have been evaluated
in Phenylketonuria (PKU) as either an adjunct to or substitute
for a low-phenylalanine diet .The nature of amino acid compo-
sition of dietary proteins contributes to cerebral function and
play a major role in affecting the brain in neurodegenerative
disorders [6]. In individuals with disease states like phenylke-
tonuria, hepatic encephalopathy, bipolar disorder, and otherneurological diseases, BCAAs supplementations have been
given to diminish or to retard the progression of central
nervous system functional symptoms. In addition, oral BCAAs
supplements have been examined as a treatment for patients
with tardive dykinesia [7], amyotrophic lateral sclerosis [8],
spinocerebellar degeneration [9] and X-linked adrenoleukodys-
trophy [10].
Since BCAAs cannot be synthesized de novo, they must be
obtained from the diet for protein synthesis [11].
In the present study we tried to use a protein substitution
technique to synthesize a new processed cheese rich in
branched-chain amino acids, with low phenylalanine content
and improved protein quality. This cheese can be of nutritional
importance as a supplement in some medical and genetic disor-
ders in liver and brain affection.2. Materials and methods
Phenylalanine-free commercial milk formula MD mil MD
PKU.O: was obtained from Liptis Pharmaceuticals, USA.
Chemicals:
1. L-Phenylalnine for mutagenesis was obtained from Aldrich-
Chemie GmbH & Co (Germany).
2. Kits for total cholesterol, LDL, triglycerides, total protein,
albumin, Aspartate Transaminase (AST) and Alanine
Transaminase (ALT) were obtained from Biodiagnostic,
Giza, Egypt. All other chemicals used through analysis
were obtained from (Sigma Chemical Co., P.O.
Box 14508, St. Louis, USA).
Experimental animals: To avoid any potential confounding
difference due to sex and age, only adult female Begg Albino
strain c (BALB/c) mice were obtained from Research Institute
of Ophthalmology, Giza, Egypt.
2.1. Processed cheese manufacture
A suitable amount as described in Table 1 of mature Ras
cheese, Karish cheese, butter oil, emulsifying salt and the
Table 1 Amount of the ingredients (g) used in manufacture of processed cheese.
Component 2.5% Protein
substitution in cheese
5% Protein
substitution in cheese
10% Protein
substitution in cheese
Cheese without
protein substitution
Ras cheese 350 312.5 225 375
Kariesh cheese 462.5 387.5 250 562.5
phenylalanine-
free milk
31.25 62.5 125 –
Emulsiﬁed salt 31.25 31.25 31.25 31.25
Fat 123.875 134.87 162.25 115
Water 251.125 321.375 456.5 166.25
pH 5.8 5.8 6.2 5.8
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2.5%, 5%, 10% consecutively in a laboratory processing ket-
tle. Control treatment was adjusted to have the same composi-
tion without adding the phenylalanine-free milk formula. The
mixture was cooked for 10 min at 85–90 C using indirect
steam at pressure 2–2.5 kg/cm2. The melted processed cheese
was poured into wide mouth glass jars and capped directly
after ﬁlling. The resultant cheese was analyzed when fresh
and stored in the refrigerator (5 ± 2 C) during the animal
experimental study.
Chemical analysis:Moisture, protein, ash, fat and titratable
acidity of the cheese were determined according to AOAC
[12]. The pH values were measured using a digital pH meter
model SA 720 (Orion, USA). Amino acid analysis by HCl
hydrolysis was performed when required, previous to amino
acid derivatization; using 6 N HCl for 21 h at 110 C in sealed
glass ampoules.
Rheological properties: Oil separation index of the pro-
cessed cheese was determined as described by Thomas [13].
The diameter of the separated oil was measured in millimeter
and used as an oil separation index. Cheese meltability was
measured as described by Olson and Price, [14] with the mod-
iﬁcation of Rayan et al. [15] using the meltability test appara-
tus. Cheese ﬁrmness was measured using a penetrometer cone
and was adjusted to touch the sample for 5 s. The penetration
depth was recorded in units of 0.1 mm. Penetrometer reading
is related inversely to ﬁrmness of the cheese spread [16].
Sensory evaluation: Samples of processed cheese were sub-
jected to sensory evaluation according to the scheme of Mayer
[17] by 15 regular scoring panel.
Animal experiment: Thirty-three BALB/c mice 3 weeks old
were raised in The Research Institute of Ophthalmology, Giza,
Egypt. The mice were given a standard diet as described by
Campbell [18] for 1 week (adaptation period) under normal
healthy conditions. At the end of the adaptation period, mice
reached an approximate weight of 24–27 g (average 25.2 ±
1.2 g). The animals were housed in cages at room temperature
(about 25 ± 5 C).
Design of experiment: After the adaptation period, three
mice were randomly chosen as a control for normal mice then
weighed. Blood samples were withdrawn from retro bulbar
venous plexus of each mouse according to the procedure of
Shermer [19], then the mice were slaughtered and liver and
brain, were excised, weighed and stored until biochemical
analysis. The other thirty mice were fed on a mutagenic diet
consisting of standard diet plus 0.3% phenylalanine (as an
inhibitor to phenylalanine hydroxylase enzyme) to induce
hyperphenylalaninemia according to Schott et al. [20] andAustic et al. [21] for additional 2 weeks. Five mice were
randomly selected and sacriﬁced in order to do biochemical
analysis and histopathological study to the liver and brain after
mutagenesis (at zero time). The other 25 diseasedmice were then
divided into ﬁve groups according to the following scheme:
Group (1) Fed on the processed cheese with 2.5%protein sub-
stitution for 3 weeks.
Group (2) Fed on the processed cheese with 5% protein sub-
stitution for 3 weeks.
Group (3) Fed on processed cheese with 10% protein substi-
tution for 3 weeks.
Group (4) Fed on processed cheese without protein substitu-
tion for 3 weeks.
Group (5) Fed on the phenylalanine-free formula milk alone
for 3 weeks.
Phenylalanine level: Phenylalanine level was estimated in
blood of mice every week (51 samples) according to McCaman
and Robbins [22] using HPLC equipment Wallac ﬂuorometer
system (Perkin-Elmer Life Science Inc., Norton, OH, USA).
Histological sections: Animals were slaughtered. Liver and
brain were quickly removed and immediately potted in chloro-
form. Liver and brain sections were prepared, stained and
viewed as described by Mahfouz et al. [23].
Serum analysis: The obtained serum from BALB/c mice
was analyzed for total cholesterol, Low density lipoprotein
cholesterol (LDL) and triglycerides using enzymatic colorimet-
ric method according to Trinder [24] and as described by Lin
et al. [25]. Total protein content was determined using the
method of Henery [26]. Albumin content was determined using
method of Doumas et al. [27].
Colorimetric method was used to determine AST and ALT
testing for liver function according toReitman andFrankel [28].
Statistical analysis:Duncan and Dunnett t-test were used to
determine statistical signiﬁcance among the different tested
mice groups. The results were presented as the mean ± the
mean; P values <0.05 were considered signiﬁcant and
P< 0.01 highly signiﬁcant.3. Results
The protein content was reduced to 7.427 mg/g in the 10%
protein substitution sample (about 49.5% of the control cheese
without protein substitution). Moisture content was kept con-
stant (at 60%) and the fat content ranged between 16.5% and
17% in all of the processed cheese formulas with various
Table 2 Chemical analysis of the manufactured processed cheese.
Constituent 2.5% Protein
substitution
in cheese
5% Protein
substitution
in Cheese
10% Protein
substitution
in Cheese
Control cheese
without protein
substitution
Acidity (%) 2.1 1.7 1.2 1.1
Protein
(mg/g)
11.469 9.7 7.427 15
Ash (%) 4.16 4.05 3.385 4.68
Moisture
(%)
60 60 60 60
Fat (%) 16.5 17 17 16.5
124 H.A.M. El-Shazly et al.grades of protein substitution (2.5%, 5% and 10%) compared
to the control cheese without protein substitution (Table 2).
The rheological properties (meltability, penetration and oil
separation) of processed cheese containing the phenylalanine-
free milk formula were higher than those of the control cheese
without protein substitution. The melting value was increased
with increasing percentage of protein substitution being high-
est in 10% substitution sample. The lowest penetration value
was found in control cheese without protein substitution, while
the highest was noticed with protein substitution treatment
(10%) followed by 5% then 2.5%. This means that control
treatment was the ﬁrmest while 10% substitution was the soft-
est. Sensory evaluation of the processed cheese indicate that
cheese control without protein substitution ranked the highest
scores for different sensory attributes and highly accepted toTable 3 Sensory and rheological evaluation of the processed chees
Evaluation 2.5% Protein
substitution in
cheese
5% P
subst
chees
I-sensory
Flavor (40) 35 36
Body (40) 35 36
Appearance (20) 18 19
Total score 88 91
II-rheological
Meltability (cm) 10 11.1
Penetration (ml) 36 47
Oil separation (%) 282.3 337.5
Diagram 1panelists, followed by the other treatments. Addition of 5%
protein substitution to cheese improved the ﬂavor, body and
texture as well as cheese appearance of the resultant spreads.
Increasing the ratio of added protein substitution led to less
acceptable products being lowest at 10% cheese protein substi-
tution (Table 3 and Diagram 1).
The highest content of branched chain amino acids (valine,
leucine and Isoleucine) was attained in the processed cheese
with 10% protein substitution along with 71.96% reduction
in the content of phenylalanine (309.78 mg/g) as compared
to 1104.56 mg/g in the processed cheese without protein substi-
tution (Table 4).
There was a highly signiﬁcant reduction in the mean value
of phenylalanine (P< 0.01) as well as signiﬁcant increase in
weight (P< 0.05) among the mice groups at zero time before
treatment and those mice groups that received treatment for-
mulas as compared with both of the positive control and dis-
eased mice groups. The highest reduction in phenylalanine
was attained with the phenylalanine-free milk (Table 5 and
Diagram 2).
There was a signiﬁcant improvement in the mean values of
total protein, serum albumin and liver enzymes among dis-
eased mice groups receiving treatment formulas with better
values obtained among those mice fed on 10% protein substi-
tution cheese as compared with positive control group. On the
other hand, there was no signiﬁcant difference as regards level
of total cholesterol, LDL-C and triglycerides (P> 0.05)
(Table 6).
Figs. 1–8 and Table 7 show the histopathological ﬁndings in
(a) the brain and (b) liver of BALB/c mice before and after
feeding on 2.5%, 5% and 10% protein substitution cheese as
compared to low-protein formula feeding group.e samples.
rotein
itution in
e
10% Protein
substitution in
cheese
Control cheese
without protein
substitution
31 38
32 37
16 19
79 94
11.5 9.2
49 31
376.4 214.4
Table 4 Amino acid analysis of different processed cheese samples vs cheese without protein substitution (mg/g).
Amino acid Control cheese
without protein
substitution
2.5% Protein
substitution
in cheese
5% Protein
substitution
in cheese
10% Protein
substitution
in cheese
Aspartic 1113.04 802.72 883.44 954
Threonine 634.08 390 424.64 456.36
Serine 831.6 484.4 473.04 637.68
Glutamic 2805.28 2166.08 2393.2 2350.4
Glycine 219.12 143.28 155.04 167.76
Alanine 562.56 345.28 386.64 403.04
Valine 768.72 489.36 588.48 1348.08
Methionine 445.2 49.52 100.64 55.6
Isoleucine 725.92 486.32 498.32 1114.88
Leucine 1584 1114.32 1138.4 2458.08
Tyrosine 1110.08 690.96 783.84 788.24
Phenylalanine 1104.56 840.4 624.4 309.68
Histidine 764.64 403.2 505.12 570.88
Lysine 1226.88 753.76 866 880
NH4 1715.2 1454.4 1585.76 1534.56
Arginine 579.92 386 385.28 448.32
Proline 5900.5 3705.049 4250.239 245.864
Table 5 Mean values of weight and phenylalanine levels in all of the mice groups before and after feeding on different cheese
substitution samples.
Value 0-Time Diseased for
2 weeks
2.5% Substitution
in cheese
5% Protein substitution
in cheese
10% Protein substitution
in cheese
+ve
Control
Ph.al.
free milk
P-value
Weight (g) 25.2 ± 1.2 19.433 ± 3.5 22.8 ± 2.2 23.8 ± 3.1 24.66 ± 2.5 17.8 ± 1.9 22.2 ± 2.9 P< 0.05
Ph.al.
(mg/d)
2.274 ± 0.84 5.79 ± 0.98 3.314 ± 1.1 2.166 ± 0.8 1.822 ± 0.42 6.2 ± 1.32 1.291 ± 0.3 P< 0.01
Diagram 2
Table 6 Mean values for biochemical ﬁndings in all of the mice groups before
Findings 0-Time Diseased for 2
weeks
2.5% Protein
substitution in cheese
5% Prot
in cheese
Total protein (g/dl) 5.986 ± 1.11 3.2 ± 0.52 3. 6 ± 0.41 4.9 ± 0.
Albumin (g/dl) 2.7 ± 0.96 1.44 ± 0.61 1.72 ± 0.56 2.25 ± 0
Total cholesterol 94.9 ± 7.2 85.9 ± 9.8 88.1 ± 6.9 89 ± 10
LDL-C 34.5 ± 3.5 32.1 ± 4.66 33.21 ± 4.9 33.41 ±
Triglycerides 116.8 ± 10.1 152 ± 8.2 121 ± 9.98 118.2 ±
AST(U/ml) 41.7 ± 2.2 90 ± 3.32 45.2 ± 2.11 44.3 ± 3
ALT (U/ml) 35 ± .99 83 ± 1.9 48 ± 3.0 38.7 ± 3
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The aim of the present study was to synthesize a new processed
cheese as a dairy product rich in branched-chain amino acids
and high quality protein for patients with the liver disease.
Mesejio et al. [2] recommended the use of branched-chain
amino acids supplementation derived from either diets with
vegetable proteins or dairy proteins to slow the progression
of liver disease and improve survival of patients with compen-
sated cirrhosis and encephalopathy. The branched-chain ami-
no acids (BCAAs) are required for protein synthesis and
neurotransmitter synthesis. BCAAs cannot be synthesized de
novo and must, therefore, be obtained from the diet for pro-
tein synthesis. Leucine is of special interest because it promotes
protein synthesis, inhibits protein degradation, and stimulates
insulin release. As a result of these actions of leucine, BCAAsand after feeding on the cheese samples.
ein substitution 10% Protein
substitution in cheese
+ve Control Ph.al.Free
milk
P-
value
63 5.2 ± 0.641 1.96 ± 0.32 3.8 ± 0.784 P< 0.05
.88 2.4 ± 0.48 0.9 ± 0.08 1.63 ± 0.43 P< 0.05
.1 96.2 ± 8.87 83 ± 7.9 79 ± 8.2 P> 0.05
3.2 34 ± 2.87 38 ± 4.66 30 ± 1.99 P> 0.05
8.91 119.1 ± 7.93 201 ± 12.97 148 ± 13.22 P> 0.05
.49 42 ± 1.88 95 ± 6.1 39 ± 2.0 P< 0.01
.2 37 ± 2.98 87 ± 5.4 37.2 ± 2.8 P< 0.05
Figure 1 (a) The brain histopathology: brain of normal BALB/c mice showing no histopathological changes (stained with H and E)
(X200). (b) The liver histopathology: liver of control normal BALB/c mice having normal histological structure of hepatic lobule (stained
with H and E) (X200).
Figure 2 (a) The brain histopathology: brain from affected BALB/cmice group at zero time after mutagenesis showing necrosis of neurons
associated with focal gliosis (stained with H and E) (X200). (b) The liver histopathology: liver from affected BALB/c mice group at zero time
after mutagenesis showing necrosis of hepatocytes, pyknosis of their nuclei and focal hepatic hemorrhage (stained with H and E) (X200).
Figure 3 (a) The brain histopathology: brain of BALB/c mice from+ve control group showing necrosis and focal gliosis (stained with H
and E) (X200). (b) The liver histopathology: liver of BALB/c mice from+ve control group showing multifocal hepatic necrosis associated
with leucocytic cells inﬁltration (stained with H and E) (X200).
Figure 4 (a) The brain histopathology: brain of BALB/c mice from group 1 showing neuronal edema (stained with H and E) (X200). (b)
The liver histopathology: liver of BALB/c mice from group 1 showing hemorrhage and necrosis of sporadic hepatocytes (stained with H
and E) (X200).
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Figure 5 (a) The brain histopathology: brain of BALB/c mice from group 2 showing necrosis of neurons associated with diffuse gliosis
(stained with H and E) (X200). (b) The liver histopathology: liver of BALB/c mice from group 2 showing no histopathological changes
(stained with H and E) (X200).
Figure 6 (a) The brain histopathology: brain of BALB/c mice from group 3 showing pyknosis of neurons (stained with H and E) (X200).
(b) The liver histopathology: liver of BALB/c mice from group3 revealed sporadic necrosis of hepatocytes with resorption of hemorrhage,
restoration of architecture of lobules, nuclei and inhibition of inﬂammation in the hepatocytes (stained with H and E) (X200).
Figure 7 (a) The brain histopathology: brain of BALB/c mice from group 4 showing cellular edema and diffuse gliosis (stained with H
and E) (X200). (b) The liver histopathology: liver of BALB/c mice from group 4 showing focal hepatic necrosis associated with leucocytic
cells inﬁltration (stained with H and E) (X200).
Figure 8 (a) The brain histopathology: brain of BALB/c mice from group 5 showing neuronal degeneration and neuronophagia (stained
with H and E) (X200). (b) The liver histopathology: liver of BALB/c mice from group 5 showing vacuolar degeneration of hepatocytes
(stained with H and E) (X200).
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Table 7 Histopathological ﬁndings in the brain and liver of mice groups before and after feeding on the protein substitution cheese
compared to the group fed on the low-protein phenylalanine-free formula.
Group Findings
I-liver
Normal mice Normal hepatic lobules
Aﬀected mice 0-time Necrosis of hepatocytes/pyknosis of nuclei/focal hemorrhage, multifocal necrosis with leukocytic inﬁltration
Group 1 Necrosis of sporadic hepatocytes
Group 2 No remarkable changes from group 1
Group 3 Sporadic necrosis/resorption of hemorrhage /restoration of hepatocytes architecture.
Group 4 Focal necrosis with leukocytic inﬁltration
Phe.al. free milk Vacuolar degeneration of hepatocytes.
II-brain
Normal mice Normal histological ﬁndings of brain cells
Aﬀected mice 0-time Necrosis of neurons/focal gliosis
Group 1 Edema of neurons/mild to moderate gliotic cells
Group 2 Necrosis of neurons/diﬀuse gliosis
Group 3 Pyknosis of neurons
Group 4 Cellular edema
Phe.al. free milk Neuronal degeneration neuronophagia
Phe.al. = phenylalanine.
128 H.A.M. El-Shazly et al.have therapeutic potential, because they spare lean body mass
during weight loss, promote wound healing, and decrease mus-
cle wasting with aging [29]. Altered amino acids metabolism is
a hallmark of liver diseases and liver cirrhosis, characterized by
low levels of circulating BCAAs and elevated levels of circulat-
ing aromatic amino acids [11]. These abnormalities are known
to induce hepatic encephalopathy and muscular waste. The eti-
ology of such abnormal amino acids metabolism is multifacto-
rial including protein restricted diet or inadequate nutritional
intake as in protein energy malnutrition. Therefore, BCCAs
supplementation seems to be useful to improve plasma amino
acids imbalance, protein energy malnutrition, and subse-
quently survival rate of cirrhotic patients [30].
In the present study, processed cheese was selected as a pos-
sible nutritional source of branched-chain amino acids
(BCAAs) since it is becoming increasingly the popular cheese
worldwide with continuous increase in its production [16]. In
Egypt, processed cheese has recently become a popular cheese
type. In 1997, it represented about a quarter of the total cheese
imports of 120,000 tons and its production either spreadable or
block type has reached about 10,000 tons in the governmental
and private sectors [31]. Using a palatable formulation, the
investigators demonstrated that long-term BCAAs supplemen-
tation is associated with decreased frequency of hepatic failure,
however, cost and palatability may limit applicability of this
type of treatment modalities. Therefore, processed cheese –
as a signiﬁcant source of protein and other nutrients – repre-
sents an attractive dairy product for several consumers espe-
cially for children [16].
In the present work, the selection of a phenylalanine-free,
low-protein formula to be used in the production of this pro-
cessed cheese may make it potentially useful for use in condi-
tions needing low protein and or low-phenylalanine in diet.
The low-phenylalanine diet is maintained relatively easily
during periods of rapid growth in infancy and early child-
hood. As somatic growth slows and the utilization of phen-
ylalanine decreases, it becomes increasingly difﬁcult to
achieve and maintain low serum phenylalanine [32]. Diet
for life has been difﬁcult because strict dietary regimensleads to erosion of dietary adherence as children get older.
This has caused reassessment of treatment strategies and
prompted the National Institute of Health Recommenda-
tions for treatment guidelines [33]. Lower levels of BCAAs
(along with large neutral amino acids) have been reported
in patients with PKU and PKU mice [34]. Motor and cog-
nitive functioning improved with addition of Valine, Isoleu-
cine and leucine supplements to the low-phenylalanine diet
[32].
The amino acids analysis of the processed cheese with 10%
protein substitution revealed high content of Valine
(1348.08 mg/g), Isoleucine (1114.88 mg/g) and Leucine
(2458.08 mg/g) compared to the 2.5% and the 5% substitution
products. The ratio between Leucine and Isoleucine 2.2:1 while
it is 1:1.2 between Isoleucine and Valine.
This is in consistency with Baker [35] who stated that most
studies involving pharmacologic BCAAs administration have
used mixtures containing 50–100% more Leucine than Isoleu-
cine, and generally slightly more Valine than Isoleucine. The
requirement ratios of the estimated average requirement
(EAR) estimates of the Dietary Recommended Intake (DRI)
Committee (2002) are 2.3 (Leucine):1.0 (Isoleucine):1.3
(Valine). The relation of one BCAAs to another (i.e., BCAAs
ratios) is of interest since pharmacologic BCAAs dosing for
muscle endurance or for other purposes generally has involved
administration of all three BCAAs [36,37]. The Daily Recom-
mended Intake (DRI) Committee [38] arrived at the estimated
average requirement (EAR) of 34, 15, and 19 mg/kg/day for
Leucine, Isoleucine, and Valine, respectively. The University
of Toronto group also reported that the BCAA requirement
of young children was 48% higher than the Daily Recom-
mended Intake (DRI) Committee recommendation [39]. No
deﬁnitive graded dosing studies with humans exist, but there
are a few instances where BCAAs dosing of 2–3 times the
EAR have been reported. Marchesini [40] treated 20 chronic
hepatic encephalopathy patients for 6 months, with an enteral
supplement providing 240 mg/kg/day of BCAA. This report
contains no reference to either toxicity or adverse effects. Pa-
tients with sepsis, stress, or injury have likewise been treated
Protein substitution to produce a processed cheese with high branched-chain amino acids 129with parenteral solutions containing up to 50% of the AA
nitrogen as BCAAs, with no apparent adverse side effects. It
appears based on both animal and human studies that BCAAs
are among the best tolerated of all amino acids when intakes
well above the requirement are consumed. Animal graded dos-
ing studies together with human single dosing studies suggest
that BCAA intake levels of at least three times the requirement
level are well tolerated [41,35].
In the present work, low-protein formula was utilized to
make different grades of protein substitutions (2.5%, 5%
and 10% protein substitution in the processed cheese) then
their effects were compared among the different affected and
control mice groups. Signiﬁcantly higher improvement was ob-
served in blood protein level among mice fed on the cheese
with 10% protein substitution.
Several investigators have suggested that high concentra-
tions of certain amino acids in plasma or brain may provide
a signal for reduction of protein consumption [42]. Peters
and Harper [43] observed a strong correlation between protein
intake of rats and concentrations of branched-chain amino
acids in plasma and brain and suggested that changes in plas-
ma or brain BCAA concentrations might serve as a signal for a
change in protein intake. On the other hand, Anderson and
Associates [44] stated that elevated plasma and brain BCAA
concentrations were not associated consistently with altered
protein selection or changes in food intake. The most impor-
tant dietary factor impacting BCAA tolerance levels is protein
level. The human maintenance BCAA requirement estimates
range from 10.3% to 22% of the maintenance protein require-
ment [35]. The current recommended dietary allowance (RDA)
for protein is 0.8 g/kg/d for adults or about 56 g protein /d for
a 70 kg person. The daily intake of the BCAAs in a 70-kg per-
son consuming the RDA for protein would thus be 8.4–11.2 g.
[45]. MacDonalds and Associates [5] concluded that in PKU
patients, a higher dosage of the protein substitute appeared
to contribute to lower phenylalanine concentrations but it
did have a variable and individual impact and may have been
inﬂuenced by the carbohydrates and fat content of the protein
substitute.
In the present study, we used L-phenylalanine in BALB/c
mice model to induce elevation in liver enzymes, hyperphenyl-
alaninemia, beside affection of the growth and liver pathology.
Schott et al. [20] stated that activity of liver phenylalanine
hydroxylase was decreased in animals receiving phenylalanine.
In animals treated with phenylalanine alone concentration of
serum phenylalanine was raised about 7-folds and triglyceride
content of the liver slightly above the control. The most obvi-
ous side effect was growth retardation and fatty liver [20]. The
liver responds to changes in nutrient availability by initiating a
number of stress signaling pathways [46]. Cell damage by oxy-
gen radicals and lipid peroxidation play a crucial and causative
role in the pathogenesis of several acute and chronic diseases,
such as cancer, aging, atherosclerosis and liver injury [47]. He-
patic illnesses in general provoke concomitant increases of
Alanine Transaminase (ALT) and Aspartate Transaminase
(AST) levels and increase in serum ALT activity are rarely ob-
served in conditions other than liver illness [48]. Studies in hu-
mans showed that oxidative stress occurs also in patients with
phenylketonuria probably contributing to the neurological
damage in this disorder. Exposure to high phenylalanine con-
centrations for a short or long time results in a reduction of
enzymatic and non-enzymatic antioxidant defenses, whereasprotein and lipid oxidative damage only occurs in patients with
late diagnosis [49].
The present study showed decrease in total serum protein,
albumin and cholesterol while LDL-C and triglycerides were
insigniﬁcantly elevated above the control after induction of
hyperphenylalaninemia (P> 0.05). Best normalization and
approximation to normal control values of protein
(P< 0.05) and cholesterol proﬁle (P> 0.05) was obtained
in the mice fed on 10% substitution formula compared to
the other formulas.
Colome´ et al. [50] stated that serum cholesterol concentra-
tions were signiﬁcantly lower in PKU patients compared with
inborn errors of metabolism patients (whose cholesterol daily
intake was similar to those of PKU patients), children with
hyperphenylalaninemia and the control group. A negative cor-
relation was observed between cholesterol and phenylalanine
concentrations in the PKU patients supporting the hypothesis
of a relationship between high plasma phenylalanine levels
and an inhibition of cholesterogenesis, although the low cho-
lesterol intake of the special diets may also decrease serum
cholesterol values. Furthermore, blood cholesterol levels of
these children were low in comparison with the levels of
healthy children of the same age, but the triglyceride levels
were higher as a result of the special diets containing a large
amount of carbohydrates [51]. Previous reports have suggested
that elevated levels of phenylalanine inhibit cholesterol [52].
However, Terry et al. [53] added that lipoprotein abnormali-
ties noted between unrelated subjects with and without
phenylketonuria are rather due to a genetic predisposition of
the population with phenylketonuria toward lower serum lipid
concentrations.
The use of 10% substitution formula with more content of
branched-chain amino acids resulted in a 26.89% gain in
weight of mice compared to 22.24% among mice fed 5% pro-
tein substitution cheese and only 17.3% in the group fed 2.5%
protein substitution cheese formula.
An anabolic effect of leucine and the branched-chain amino
acids was found on reduction of muscle protein breakdown in
humans [54]. Similar studies in liver showed stimulation of
protein synthesis by leucine and a reduction in protein
break-down [55]. Ingestion of BCAAs increases their concen-
tration in plasma. This may reduce the uptake of tryptophan
by the brain and also 5-HT synthesis and thereby delay fatigue.
Accordingly, when BCAAs were supplied to human subjects
during a standardized cycle ergometer exercise (to measure
the amount of work and energy expenditure done by the mus-
cles over a period of time) their ratings of perceived exertion
and mental fatigue were reduced [56]. Cangiano et al. [57]
hypothesized that the oral administration of BCAAs to cancer
patients with anorexia would lead to decreased brain trypto-
phan concentrations and reduced serotoninergic activity, even-
tually resulting in an improvement of food intake and,
therefore, BCAAs may be used safely to improve caloric intake
in cancer patients with anorexia. The BCAAs are central in the
maintenance of lean body mass and regulation of skeletal mus-
cle protein metabolism [4].
In the present study, there was a reduction in the serum
phenylalanine by 68.5% in the mice group fed on cheese with
10% protein substitution compared to 77.7% in group fed on
phenylalanine free formula with less reductions in the mice
groups fed 5% (62.5%) and 2.5% protein substitution cheese
(42.7%), respectively.
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tion by modifying large, neutral amino acid (LNAA) transport
at the blood–brain barrier. Transport is shared by several
LNAAs, notably the BCAAs and the aromatic amino acids
(ArAAs), and is competitive [58]. The use of BCAAs dietary
‘‘supplements’’ has been examined as a means to promote
reductions (or further reductions) in brain phenylalanine con-
centrations. The notion is that by elevating plasma concentra-
tions of the BCAAs, brain phenylalanine (PHE) uptake can be
diminished (or further diminished), thereby producing reduc-
tions in brain phenylalanine concentrations and a beneﬁcial ef-
fect to brain function. The chronic use of BCAA supplements
has been evaluated in PKU subjects as either an adjunct to or
substitute for a low-PHE diet (e.g., in patients unable to main-
tain the rather restrictive low-PHE diet) for up to 6 weeks in
four divided daily doses totaling 500 mg/kg/d. This treatment
signiﬁcantly elevated plasma and cerebrospinal ﬂuid (CSF)
concentrations of the BCAAs and reduced CSF concentrations
of both PHE and TYR in adolescents and adults [59,60]. This
treatment paradigm was associated with no adverse effects,
and improvements in some cognitive functions were noted
[32]. The highest doses of BCAAs that have been administered
chronically to humans have been to PKU [up to 35 g/d] [59]
and in patients with mania [up to 60 g/d] [32].
The histopathological ﬁndings were improved more in the
liver and brain sections of mice from group 3 (fed on cheese
with 10% protein substitution) than the remaining mice
groups as revealed in the liver by the resorption of hemor-
rhage, restoration of architecture of lobules and inhibition of
inﬂammation in the hepatocytes and in the brain by the regres-
sion of inﬂammatory and cellular edema together with areas
showing signs of necrosis.
Infusion of BCAAs in patients with hepatic cirrhosis
blocked the abnormal uptake of tyrosine by the brain [61].
Furthermore, administering valine to rats prevented the exer-
cise-induced 5-HT release in the ventral hippocampus during
and after exercise [62]. Both studies indicate that elevating
the plasma concentration of BCAAs (or valine) decreases the
transport of the aromatic amino acids, tyrosine and trypto-
phan, into the brain as can be predicted from our knowledge
of transport competition through the blood–brain barrier [58].
The administration of branched-chain amino acids stimu-
lates hepatic protein synthesis, reduces post injury catabolism
and, therefore, improves nutritional status. Inadequate protein
intake has a very deleterious effect on hepatic encephalopathy,
nutritional status and clinical outcome of patients with liver
disease [63]. Studies on inter-organ ammonia exchange in liver
cirrhosis have shown that muscles may have a crucial role in
ammonia detoxiﬁcation. Nutritional guidelines have proposed
that protein restriction should be avoided in patients with he-
patic encephalopathy as protein requirement is even increased
in cirrhotic patients [1].
Mesejio et al. [2] stated that in patients with liver cirrhosis
and encephalopathy, metabolic impairment mimics a hyper-
catabolic state with increased protein and fat catabolism
leading to depletion of protein and lipid reserves. Khanna
and Gopalan [64] stated that there is ample evidence that pa-
tients with liver disease have an ongoing energy and protein
catabolism.
Mesejio et al. [2] stated that protein restriction is not indi-
cated in compensated cirrhosis. In acute encephalopathy tem-
porary protein restriction may be needed, which should notlast longer than 48 h. Better outcomes are obtained without se-
vere protein restriction. Oral supplementation with branched-
chain amino acids slows the progression of liver disease and
improves survival and quality of life. On balance, branched
chain amino acids (BCAAs) supplementation appears to be
associated with decreased frequency of complications of cir-
rhosis and associated with improved metabolic proﬁles and
clinical improvement of hepatic encephalopathy when pre-
scribed as maintenance therapy [11]. Khanna and Gopalan
[64] reported that the administration of BCCAs stimulates he-
patic protein synthesis in patients with chronic liver disease
with no reported toxic effects and added that the beneﬁcial role
of branched-chain amino acids supplementation in patients
with chronic hepatic encephalopathy has been clearly docu-
mented. The FOXA (forkhead box A) proteins (FOXA1,
FOXA2 and FOXA3) play a critical role in the development
of the liver and they also regulate metabolism in adult hepatic
tissue. Hepatic FOXA family of genes is differentially regu-
lated by amino acids availability [46].
The rheological properties (meltability, penetration and oil
separation) of processed cheese containing phenylalanine-free
formula were higher than those of the control cheese without
protein substitution. The melting value was increased with
increasing percentage of the added protein substitution being
highest in the processed cheese with 10% protein substitution.
The higher melting value of processed cheese containing pro-
tein substitution may be due to its low casein and total protein
contents [65].
The fat separation increased with increasing the added per-
centage of protein substitution in the formulae which could be
attributed mainly to the nature of protein substitution in prod-
uct. The protein matrix of Ras cheese (mainly casein) is able to
retain fat and other components while protein substitution
would weaken the matrix to be less able to retain the fat.
The lowest penetration value was found in control cheese with-
out protein substitution, while the highest was noticed with
protein substitution cheese with 10% substitution followed
by 5% then 2.5%. This means that control treatment was
the ﬁrmest while 10% substitution was the softest. The differ-
ence in penetration value between control and treatments with
protein substitution are mainly due to the cheese base used
phenylalanine-free milk formula contained high soluble nitro-
gen that led to softer cheese [66].
In contrast, sensory evaluation of processed cheese indicate
that cheese control without protein substitution was ranked the
highest scores for different sensory attributes and highly ac-
cepted to panelists, followed by other treatments. Addition of
5% protein substitution of cheese improved the ﬂavor, body
and texture as well as cheese appearance of the resultant
spreads which may make its rheological properties suitable
for utilization by patients who are vomiting. It is difﬁcult to
give orally the usual quantity of BCAA free supplement partic-
ularly if the child is vomiting where the alternative is to use con-
tinuous nasogastric feeding [67]. On the other hand, increasing
the ratio added protein substitution led to less acceptable prod-
ucts being lowest at 10% cheese base substitution.
In the present study, the improvement in brain pathology
was best achieved in the mice fed on the processed cheese with
10% protein substitution. Branched- chain amino acids have
been reported to improve fetal brain development in a rat
model in which maternal PKU is induced by the inclusion of
L-phenylalanine in diet [21]. Untreated patients with PKU
Protein substitution to produce a processed cheese with high branched-chain amino acids 131have been reported to have lower brain weights, changes in
myelin structure, reductions in dendritic arborization and
numbers of synaptic spines with selective vulnerable regions
of the brain and disaggregation of brain ribosomes along with
reduced polypeptide chain elongation on the polyribosomes of
the brain. These effects are reversed by treatment of the mice
with mixture of neutral amino acids including branched-chain
amino acids [68]. The increased white matter water content has
been suggested to reﬂect edema associated with gliosis within
the tissue with defective myelination and status spongiosis
[69]. There is dramatic increase in myelination after return of
blood and brain phenylalanine to near normal control values
[70]. The BCAAs increased in the brain as dietary casein level
was increased. The magnitude of the responses in brain is
approximately one-half the response in serum [71]. The inges-
tion of BCAAs causes rapid elevation of their plasma concen-
trations and increases their uptake by the brain [72]. Oral
BCAA treatment has been applied to patients with stable he-
patic cirrhosis based on the observation that liver failure pro-
duces elevated circulating levels of the aromatic amino acids
and depressed concentrations of the BCAAs. Such changes in-
crease brain concentrations of the aromatic amino acids, pos-
sibly stimulating the production of neurotransmitters and
other biogenic amines that facilitate encephalopathy [73]. Sup-
plying BCAAs is thus seen as a means to antagonize ArAA up-
take into the brain and thus reduce the production of the
biogenic amines derived from them. Indices of mental and mo-
tor function were signiﬁcantly improved, and no adverse reac-
tions were observed [74]. BCAA treatment reduced
hospitalization, improved biochemical and pathophysiologic
signs, and reduced anorexia [75].
Oral BCAA supplements have also been examined as a
treatment for several neurologic diseases as bipolar subjects
during periods of mania, on the presumption that this treat-
ment will reduce brain tyrosine uptake and will slow catechol-
amine synthesis [76]. BCAAs have also been administered to
patients with tardive dyskinesia. The application of oral
BCAA therapy to this patient population followed from the
observation that plasma phenylalanine concentrations were
high in these patients, possibly causing abnormally high phen-
ylalanine levels in the brain and adverse neuro chemical effects.
The BCAAs have also been studied as a treatment for amyo-
trophic lateral sclerosis, BCAA administration has been
hypothesized to restore GLU dehydrogenase enzyme activity,
increase brain GLU disposal rate, and thereby diminish the
neurotoxic effects of excessive extracellular GLU [77]. In the
brain, GLU is an excitatory neurotransmitter; excessive extra-
cellular levels can over stimulate neurons, causing them to die
(excitotoxicity) [78].5. Conclusion
The manufactured processed cheese in this study can be used
as a therapeutic nutritional supplement rich in branched-chain
amino acids. Best results and rheological evaluation were ob-
tained with the 10% protein substitution in cheese while the
best sensory score for ﬂavor and appearance was for the 5%
protein substitution in cheese. This may help in the implemen-
tation of dietary management in many medical and genetic dis-
orders with liver and brain affection.References
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